An N Massaro1, Yvonne W Wu2, Theo K Bammler3, Bryan Comstock4, Amit Mathur5, Robert C McKinstry6, Taeun Chang7, Dennis E Mayock8, Sarah B Mulkey7, Krisa Van Meurs9, Sandra Juul8. 1. Department of Pediatrics, The George Washington University School of Medicine and Children's National Health Systems, Washington, DC. Electronic address: anguyenm@cnmc.org. 2. Department of Neurology, University of California, San Francisco, San Francisco, CA; Department of Pediatrics, University of California, San Francisco, San Francisco, CA. 3. Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA. 4. Department of Biostatistics, University of Washington, Seattle, WA. 5. Department of Pediatrics, Washington University, St Louis, MO. 6. Department of Pediatrics, Washington University, St Louis, MO; Department of Radiology, Washington University, St Louis, MO. 7. Department of Pediatrics, The George Washington University School of Medicine and Children's National Health Systems, Washington, DC; Department of Neurology, The George Washington University School of Medicine and Children's National Health Systems, Washington, DC. 8. Department of Pediatrics, University of Washington, Seattle, WA. 9. Department of Pediatrics, Stanford University, Palo Alto, CA.
Abstract
OBJECTIVES: To evaluate plasma brain specific proteins and cytokines as biomarkers of brain injury in newborns with hypoxic-ischemic encephalopathy (HIE) and, secondarily, to assess the effect of erythropoietin (Epo) treatment on the relationship between biomarkers and outcomes. STUDY DESIGN: A study of candidate brain injury biomarkers was conducted in the context of a phase II multicenter randomized trial evaluating Epo for neuroprotection in HIE. Plasma was collected at baseline (<24 hours) and on day 5. Brain injury was assessed by magnetic resonance imaging (MRI) and neurodevelopmental assessments at 1 year. The relationships between Epo, brain-specific proteins (S100B, ubiquitin carboxy-terminal hydrolase-L1 [UCH-L1], total Tau, neuron specific enolase), cytokines (interleukin [IL]-1β, IL-6, IL-8, IL-10, IL-12P70, IL-13, interferon-gamma [IFN-γ], tumor necrosis factor alpha [TNF-α], brain-derived neurotrophic factor [BDNF], monocyte chemoattractant protein-1), and brain injury were assessed. RESULTS: In 50 newborns with encephalopathy, elevated baseline S100B, Tau, UCH-L1, IL-1β, IL-6, IL-8, IL-10, IL-13, TNF-α, and IFN-γ levels were associated with increasing brain injury severity by MRI. Higher baseline Tau and lower day 5 BDNF were associated with worse 1 year outcomes. No statistically significant evidence of Epo treatment modification on biomarkers was detected in this small cohort. CONCLUSIONS:Elevated plasma brain-specific proteins and cytokine levels in the first 24 hours of life are associated with worse brain injury by MRI in newborns with HIE. Only Tau and BDNF levels were found to be related to neurodevelopmental outcomes. The effect of Epo treatment on the relationships between biomarkers and brain injury in HIE requires further study. TRIAL REGISTRATION: ClinicalTrials.gov: 01913340.
RCT Entities:
OBJECTIVES: To evaluate plasma brain specific proteins and cytokines as biomarkers of brain injury in newborns with hypoxic-ischemicencephalopathy (HIE) and, secondarily, to assess the effect of erythropoietin (Epo) treatment on the relationship between biomarkers and outcomes. STUDY DESIGN: A study of candidate brain injury biomarkers was conducted in the context of a phase II multicenter randomized trial evaluating Epo for neuroprotection in HIE. Plasma was collected at baseline (<24 hours) and on day 5. Brain injury was assessed by magnetic resonance imaging (MRI) and neurodevelopmental assessments at 1 year. The relationships between Epo, brain-specific proteins (S100B, ubiquitin carboxy-terminal hydrolase-L1 [UCH-L1], total Tau, neuron specific enolase), cytokines (interleukin [IL]-1β, IL-6, IL-8, IL-10, IL-12P70, IL-13, interferon-gamma [IFN-γ], tumor necrosis factor alpha [TNF-α], brain-derived neurotrophic factor [BDNF], monocyte chemoattractant protein-1), and brain injury were assessed. RESULTS: In 50 newborns with encephalopathy, elevated baseline S100B, Tau, UCH-L1, IL-1β, IL-6, IL-8, IL-10, IL-13, TNF-α, and IFN-γ levels were associated with increasing brain injury severity by MRI. Higher baseline Tau and lower day 5 BDNF were associated with worse 1 year outcomes. No statistically significant evidence of Epo treatment modification on biomarkers was detected in this small cohort. CONCLUSIONS: Elevated plasma brain-specific proteins and cytokine levels in the first 24 hours of life are associated with worse brain injury by MRI in newborns with HIE. Only Tau and BDNF levels were found to be related to neurodevelopmental outcomes. The effect of Epo treatment on the relationships between biomarkers and brain injury in HIE requires further study. TRIAL REGISTRATION: ClinicalTrials.gov: 01913340.
Authors: Aaron Sathyanesan; Joy Zhou; Joseph Scafidi; Detlef H Heck; Roy V Sillitoe; Vittorio Gallo Journal: Nat Rev Neurosci Date: 2019-05 Impact factor: 34.870
Authors: Anna C Pfalzer; Jordyn M Wilcox; Simona G Codreanu; Melissa Totten; Terry J V Bichell; Timothy Halbesma; Preethi Umashanker; Kevin L Yang; Nancy L Parmalee; Stacy D Sherrod; Keith M Erikson; Fiona E Harrison; John A McLean; Michael Aschner; Aaron B Bowman Journal: Metallomics Date: 2020-07-22 Impact factor: 4.526
Authors: L Chalak; L Hellstrom-Westas; S Bonifacio; T Tsuchida; V Chock; M El-Dib; An N Massaro; A Garcia-Alix Journal: Semin Fetal Neonatal Med Date: 2021-07-28 Impact factor: 3.726
Authors: Thomas R Wood; Phuong T Vu; Bryan A Comstock; Janessa B Law; Dennis E Mayock; Patrick J Heagerty; Thomas Burbacher; Theo K Bammler; Sandra E Juul Journal: J Cereb Blood Flow Metab Date: 2021-02-07 Impact factor: 6.200